What happened to Spero Therapeutics' shares?

They fell after a $105 million investment deal with KKR.

What is the deal worth?

The deal is worth $105 million.

KKR is a big investment company.

world1 outlet covering thisCalibrating

Spero Therapeutics shares fall after $105M KKR deal

First publishedJul 14, 10:20 UTC

Last updatedJul 14, 13:59 UTC · 12m ago

1 outlets over time — hover a bar for its window & outletslast updated

Spero Therapeutics shares fall after $105M KKR deal

● Story signals

How strong is this topic?

5.8/10Significanceimpact & urgency

6.0/10Source trustoutlet authority

1Outletsindependent sources

Significance weighs impact, urgency & coverage breadth · Source trust is the outlets' average authority · more outlets means a more confirmed story.

Answer

Spero Therapeutics shares fell after a $105 million investment deal with KKR.

Reported by 1 outlet — Investing.com · Stock Market. See all sources ↓

Spero Therapeutics, a biotech company, received a big investment from KKR. The company's shares went down after the deal. This deal is worth $105 million.

Why it matters

Investors care about this because a big deal like this can affect the company's future.

In brief

What happened to Spero Therapeutics' shares?: They fell after a $105 million investment deal with KKR.
What is the deal worth?: The deal is worth $105 million.
What is KKR?: KKR is a big investment company.

Different angles across outlets

Coverage map

How outlets are framing the same story

These are the main editorial angles found across reporting. Use them to quickly compare what different outlets emphasize, omit, or question.

Outlets frame the story as a business deal gone wrong, with some focusing on the potential risks for Spero Therapeutics.

Coverage cardFraming signal
1Angle
Scouting report
The impact on the company's future
Sources2
TypeAngle
Investing.comInvestors care about this deal's effect on Spero Therapeutics.
Stock MarketThis deal could affect the company's stock price.
Coverage cardFraming signal
2Angle
Scouting report
The role of KKR in the deal
Sources1
TypeAngle
Investing.comKKR is a big investment company that helped Spero Therapeutics.
Coverage cardFraming signal
3Angle
Scouting report
The potential risks for Spero Therapeutics
Sources1
TypeAngle
Stock MarketThis deal could put Spero Therapeutics at risk.

Related in the knowledge graph

organizationKKR organizationSpero Therapeutics

Sources (1)

Avg source rating 6.0/10

Investing.com · Stock Market6

Processing cluster

A1A2A3B1B2B3

Share this article

X / Twitter LinkedIn WhatsApp

Summarize with AI (opens AI chat with article URL · Gemini: prompt copied to clipboard)

GPT Perplexity Gemini Claude